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1. Structure of aprotinin and kinetics of inhibition 
The proteinase inhibitor aprotinin (synonym: basic pancreatic trypsin inhibitor, 
BPTI) is of a pear-shaped molecular form (Fig. l) .The inhibitor inactivates its 
target enzymes by formation of an enzyme-inhibitor complex. In this complex, 
the head region of the inhibitor ("reactive site", cf. Fig. 1) forms a tight contact 
with the cleft ("active site") of the proteinase, thereby blocking the proteolytic 
activity of the enzyme (1). As a structural pecularity of the aprotinin molecule, 
a lysine residue is located in position no. 15 of its amino acid chain (cf. Fig. 1). 
This lysine residue, which forms part of the reactive site of the inhibitor, fits 
perfectly into the corresponding specificity pocket of trypsin and of related 
proteinases, thus making aprotinin one of the most powerful inhibitors of 
trypsin-like proteinases. 
The reaction between a proteolytic enzyme (E) and the corresponding 
inhibitor (1) is characterized by an equilibrium in which the formation rate of 
the complex (EI) from the single components is balanced by the dissociation 
rate of the complex into the parental molecules E and I (cf. equation (a)) 
(a) E + I ^± EI 
The stability of the complex which reflects the affinity of the constituents for 
one another is given by the equilibrium constant K, specified by equation (b) 
where [E], [I] and [EI] are the molar concentrations of the enzyme, the 
inhibitor and the complex, respectively: 
(b> * . [ e i * m 
[EI] 
The dimension of the equilibrium constant Kj is mol/1 [MJ.The smaller the Kj 
value, the tighter the complex, i.e. minimum Kj values reflect maximum 
affinity.Typical Kj constants for complexes of aprotinin with various proteinases 
are compiled in Table 1. Among the various constants, the Kj value of 6 x 10~1 4 
mol/1 for the bovine trypsin-aprotinin complex is outstanding. The extremely 
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low Kj value indicates that the equilibrium of the reaction is shifted almost 
totally towards complex formation (cf. equation (a)) and therefore aprotinin is 
capable of completely inactivating bovine trypsin even at very low concentra-
tions. The reason for this remarkable affinity is the perfect fit of the contact 
regions of trypsin and aprotinin which are complementary in shape ("key and 
lock" hypothesis). Not surprisingly, formation of the complex does not require 
engergy; instead, an appreciable amount of energy is released upon complex 
formation. 
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Fig. 1. The tertiary structure of aprotinin according to Huber et al. and De.sienh.ofer & 
Steigemann (cited in Ref. 1). 
The aprotinin molecule has a length of 29 Ä, a diameter of 19 Ä and contains a double-stranded 
antiparallel ß-sheet structure (from Ala-16 to Gly-36) which is turned into a right-handed double 
helix with 14 amino acids per turn. Amino acids in the region of the hatched area (constituting the 
reactive site of the inhibitor) are in close contact with trypsin once the enzyme inhibitor complex is 
formed. Amino acid no. 19 (arginine) not contained in the contact area plays a major role in the 
complex formation with the kallikreins due to its inherent basic character (cf. Ref. 1). 
Positively charged amino acid side chains are present at positions 1, 15,17,20,39,39,41,42,46,53 
(n = 10): negatively charged ones at positions 3 and 50 only. 
44 H. Fritz, M. Jochum 
Table 1. Equilibrium constants Kj of enzyme-inhibitor complexes. For full references, cf. 
Ref. 1. 
enzyme source species K t (mol/1) PH 
trypsin pancreas cow 6.0 x 10 1 4 8.0 
anhydrotrypsin pancreas (a) cow (a) 3.0 x 10- 1 3 8.0 
trypsinogen pancreas cow 1.8 x 10 6 8.0 
chymotrypsin pancreas Pig 
man 
9.0 x 10 9 
6.0 x 10-y 
8.0 
7.2 
plasmin plasma Pig 
man 
man 
4.0 x 10 y (b) 
2.3 x 10 1 , 1 (b) 


















1.0 x 10- y (b) 
1.3 x 10-* (b) 
1.6 x 1 0 y (b) 
1.7 x 10 y (b) 
1.0 x 10- 7 
0.9 x 10-'° 








elastase leukocytes man 3.5 x 10- f i (c) 8.0 
urokinase urine man 8.0 x 10 6 (d) 8.8 
(a) semisynthetic enzyme 
(b) approx. values only 
(c) strongly dependent on the ion concentration (cf. Ref. 1) 
(d) Diet! T, Hugo B, Fritz H , unpublished results 
2. Effective aprotinin levels in vivo 
Aiming at clinical applications of aprotinin or related inhibitors, it is of prime 
importance to know which aprotinin concentration (s) can be reached with a 
given dosage regimen. For a long time, precise assays to quantitate aprotinin 
accurately in patients' plasma have been unavailable. To overcome this 
problem, we have developed two assays which allow the measurement of 
aprotinin concentrations in plasma and related biological fluids with high 
specificity and accuracy. Both assays, i.e. an enzymatical test (2) and an enzyme 
immunoassay (3), are suitable for routine measurements. Meanwhile, the tests 
have been successfully applied to monitor aprotinin plasma concentrations in 
several clinical trials. 
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In a first clinical study carried out in polytraumatized patients (4) a 
continuous infusion of 250.000 KlU/h (kallikrein inhibitor units per hour) 
equivalent to approx. 35 mg aprotinin per hour resulted in a mean plasma 
concentration of 50 KIU/ml (almost equalling 1 jimol/I). This value can be 
appreciated if compared with the plasma levels of endogenous proteinase 
inhibitors (Table 2). The concentrations of the major plasma proteinase 
inhibitors vary from approx. 1 pimol/1 (a2-plasmin inhibitor, oc2PI) to approx. 52 
[imol/1 (a rproteinase inhibitor, o^PI, previously known as ct rantitrypsin). 
Hence, an aprotinin concentration of 1 [imol/l inhibitor is of the same order of 
magnitude as that of the endogenous a 2 PI. 
The level of a 2PI in human plasma is low compared to that of other naturally 
occurring inhibitors (cf. Table 2). However, the a 2PI concentration can be 
elevated by inflammatory stimuli with a resulting 1.6-fold increase of the a 2PI 
plasma level. This increase in plasma concentration is brought about by the 
enhancement of a 2PI biosynthesis in the liver which is usually a matter of a few 
days. On the other hand, a major part of the endogenous a 2 PI pool can be 
rapidly "consumed1' during sepsis, polytrauma, disseminated intravascular 
coagulation (DIC), or reactive fibrinolysis. Under these conditions, restoration 
of the anti-plasmin pool by administration of an exogenous inhibitor such as 
Tabic 2. Proteinase inhibitors of human plasma, their relative molecular masses (M t ) and their 
mean plasma concentrations (acute phase proteins are in italics). 
Abbreviation inhibitor Mr 
x 1000 
mean concentration 
mg/100 ml mol/1 
a 2 M ob-macroglobulin 725 260 3.6 
a,Pl arproteinase inhibitor 50 260 52 
ex, AC a i -antichymotrypsin 70 45 6.4 
ITI inter-cx-trypsin inhibitor 160 45 2.8 
aPI a-cysteine-proteinase inhibitor 60 50 8 
ßiCI ßi-collagenase inhibitor 40 1.5 0.4 
AT I I I antithrombin I I I 65 26 4.0 
a 2PI a\-plasmin inhibitor 70 6 0.9 
CI I N A CI-inhibitor (CI-inactivator) 100 24 2.4 
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aprotinin seems useful with a resultant plasma concentration equalling that of 
the natural inhibitor under physiologcial or pathophysiological conditions 
(0.5-1.6 |imol/l). Thus, the rationale of our approach is to establish a 
sufficiently high inhibitor level under "consuming" conditions, thereby com-
pensating the loss of the endogenous inhibitor potential to prevent an 
overshoot of (potentially harmful) proteolysis right from the start. Left to the 
body itself, the "filling-up" of the inhibitor potential would take at least some 
days. 
3. Target enzymes of aprotinin in vitro and in vivo 
The question arises as to which enzymes are effectively inhibited by an 
aprotinin plasma concentration of 1 jxmol/l.This consideration is important to 
evaluate the potential therapeutic efficacy of such an aprotinin medication. 
A . Plasmin 
The Kj for the complex of human plasmin and aprotinin is very low (approx. 2.3 
x 10" 1 0mol/l). In order to assess the efficacy of aprotinin in inhibiting plasmin 
in vivo, the actual concentrations of the enzyme and the inhibitor have to be 
considered. I t is reasonable to assume that only a minor fraction of the 
plasminogen present in the plasma (concentration approx. 2 jimol/1) is activated 
even under pathological conditions. Therefore, at a given aprotinin concentra-
tion of 1 [xmol/1, one would expect the inhibitor concentration to clearly exceed 
the actual plasmin concentration, thus allowing a rapid and (almost) complete 
inhibition of plasmin liberated systemically into circulation. Also, one should 
keep in mind that a certain fraction of systemically released plasmin is inhibited 
by the endogenous inhibitors. 
Proper inhibition of systemically released plasmin (i.e. the plasmin fraction 
not locally effective on the fibrin fibre) is mandatory because this enzyme 
effectively digests plasma factors ("plasminolysis"). Among other target 
proteins, the systemically released plasmin can split and thereby inactivate 
important plasma factors (e.g. coagulation factors V and V I I I , fibrinogen, 
fibronectin), or activate them (e.g. the complement factors C I , C3 and C5). 
Especially under the conditions of DIC, systemic plasminolysis contributes to 
the proteolytic breakdown of essential clotting factors, and, as a consequence, 
loads the reticulo-endothelial system (RES) with protein degradation prod-
ucts. 
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Principally, we have to consider two pathways of plasmin action: first, the 
pathological plasminolyis e.g. of fibrinogen ("fibrinogenolysis"), and second, 
the physiologically important fibrinolysis, a process targeted at and restricted 
to fibrin. In the latter case, natural activators of plasminogen are concentrated 
on fibrin fibres of the clot, thus allowing local activation of plasminogen and 
subsequent degradation of fibrin in situ. From a clinical point of view, inhibition 
of local fibrinolysis by aprotinin is normally unwanted and an aprotinin plasma 
concentration of 1 jimol/1 is unlikely to prevent local fibrinolysis effectively for 
two reasons: (i) the plasmin concentration in situ (i.e. on the clot) is 
considerably higher than the systemic plasmin concentration, and (ii) the access 
of fibrin-associated plasmin by aprotinin is sterically restricted (5). Experimen-
tal studies to assess these hypotheses are still under way. 
B. Tissue kallikrein 
Human tissue kallikreins have affinities to aprotinin comparable to those of 
plasmin (Kj approx. 1 x 10~1 0mol/l). Since the tissue kallikreins are present in 
plasma in much lower concentrations (approx. 3 x 10~1 0mol/l) than plasmin, 
complete blockage of their enzymatic activities at 1 |imol/l aprotinin is highly 
likely. However, rigorous experimental proof of this hypothesis awaits further 
investigations. 
C. Plasma kallikrein 
Unlike the tissue kallikreins, human plasma kallikrein is much less efficiently 
inhibited by aprotinin, the Kj value of the complex being 3.0 x 10~8 mol/l.This 
equals the amount of plasma kallikrein that can be generated from its precursor 
under pathological conditions (e.g. approx. 1.5 x 10 - 8 mol/1 if 10 % of the total 
plasma kallikrein is activated). It is still an open question as to what extent the 
proteolytic activity of the plasma kallikrein against its natural substrates, i.e. 
high-molecular-weight kininogen and Hageman factor (F X I I ) , can be 
inhibited by 1 jxmol/1 aprotinin. Theoretical considerations predict that only 
aprotinin concentrations as high as 4 i^mol/1 (200 KIU/ml) will properly inhibit 
liberated plasma kallikrein (6). 
In this context, the notion of Schapira et al. (7) that plasma kallikrein can 
stimulate the aggregation of polymorphonuclear (PMN) granulocytes is worth 
mentioning. Aggregation of the PMN granulocytes may result in a massive 
shedding of lysosomal proteinases such as elastase, and according to Schapira et 
al. this effect is directly induced by plasma kallikrein and not mediated via 
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kinins. Typically , the lysosomal proteinases generate significant amounts of 
proteolytic breakdown products due to "unspecified proteolysis of plasma 
proteins. This process is entailed by a rapid loading of the RES which functions 
in the elimination of these products. Present evidence suggests that this cascade 
of events triggered by plasma kallikrein has more harmful than beneficial 
effects on homeostasis. 
Assuming that Schapira's notion (7) can be confirmed by others, a triad of 
functions has to be envisaged for plasma kallikrein: 
first, it liberates kinins from kininogens; 
second, it triggers the endogenous pathway of blood coagulation via F X I I 
activation; 
and third, it stimulates PMN granulocytes and induces release of lysosomal 
enzymes. Hence, proper regulation of plasma kallikrein activity by inhibitors 
under pathological conditions would be of special significance. 
D. Trypsin 
The Kj value for the complex of bovine trypsin and aprotinin (approx. 10 - 1 4 
mol/1) is extremely low. By analogy, one might conclude that human trypsin 
(both the cationic and anionic form) is equally well inhibited by aprotinin, 
though the exact Kj for this complex remains to be determined. Keeping in 
mind that the pancreas is the only source for trypsin, it is reasonable to assume 
that the plasma concentration of trypsin remains well below 1 fxmol/1 even under 
pathological conditions. Hence, 1 (imol/1 aprotinin should suffice to completely 
inactivate trypsin accidentally released from the pancreas under inflammatory 
conditions, e.g. in acute pancreatitis. 
E. Various enzymes 
The affinity of aprotinin for lysosomal proteinases from polymorphonuclear 
(PMN) leukocytes such as elastase or cathepsin G is too low (cf. Table 1) to 
ensure proper inhibition of these enzymes even if they are present in very small 
amounts. When these enzymes are liberated from the granulocytes by the 
stimuli of a severe trauma or a massive infection, the body supplies a number of 
far more efficient inhibitors, e.g. oil PI and a 2 M for elastase and o^AC, a 2 M a 2 
and cxi PI for cathepsin G (cf. Table 3). Similar characteristics apply to urokinase 
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Tab. 3. Target enzymes of natural plasma proteinase inhibitors (for acronyms, cf. Table 2). 
Primary target enzymes: lysosomal and pancreatic proteinases 
a 2 M all classes of proteinases, in particular 
- pancreatic trypsin 
- elastase and cathepsin G from neutrophils 
- plasma kallikrein and plasmin 
- cysteine proteinases and collagenases 
a,PI serine proteinases 
- elastase from neutrophils 
- pancreatic chymotrypsin and elastase 
- pancreatic trypsin 
a,AC serine proteinases 
- cathepsin G from neutrophils 
- mast cell chymase 
I T I serine proteinases 
- pancreatic trypsin and chymotrypsin 
aCPI (a) cysteine proteinases 
- cathepsin H , L , B, S 
- calpain 
ßiCI metalloproteinases 
- coll age nase 
Primary target enzymes: cascade proteinase 
AT I I I - thrombonin and factor Xa 
a 2PI - plasmin (cf. a 2 M) 
CI I N A - plasma kallikrein (cf. a 2 M) 
- Hageman factor 
- Clr. Cls 
(a) The two cysteine proteinase inhibitors of human plasma ( a r C P I and a2-CPI) are identical with 
H M W and L M W kininogens (Müller-Esterl et al): Human plasma kininogens are identical 
with cx-cysteine proteinase inhibitors. Evidence from immunological, enzymalical and 
sequence data. FEBS Letters 182: 310-314, 1985). 
and chymotrypsin (cf.Tables 1,3 and Ref. 1).There are, however, derivatives of 
aprotinin available which strongly inhibit lysosomal elastase (8); their thera-
peutic efficacy remains to be examined. 
4. Aprotinin effects unrelated to inhibitor function 
Apart from its role as an enzyme inhibitor, aprotinin possesses another 
extraordinary feature, i.e. an unusually high positive net charge at pH 7.4 (the 
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Fig. 2. In vivo effects of aprotinin in the blood coagulation cascade and the fibrinolytic 
system. 
Interference of aprotinin with the endogenous coagulation pathway can be observed at high plasma 
concentrations of the inhibitor. Simultaneously, the aggregation of neutrophils, the liberation of 
kinins, and the kallikrein-mediated activation of plasminogen are slowed down. A t very high 
aprotinin plasma concentrations, even platelet aggregation is reversibly inhibited. Unlike the 
endogenous pathway, the extrinsic blood coagulation cascade is virtually unaffected by aprotin-
in. 
Systemic fibrinolysis (cf. text for details) is effectively inhibited even at moderate concentrations of 
aprotinin. Also, the plasmin-mediated degradation of many plasma factors and hence the 
formation of harmful degradation products is largely prevented. By contrast, local fibrinolysis is 
not significantly affected at moderate aprotinin concentrations, and only blocked at very high 
concentrations of the inhibitor. Unlike the endogenous plasmin inhibitor a 2PI which is trapped into 
the evolving fibrin network, the access of aprotinin to the formed clot seems to be restricted. 
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isoelectric point of aprotinin is 10.5). No negatively charged amino acid 
residues are present at the apical region of the pear-shaped molecule (cf. Fig. 1) 
which thus forms a typical dipole. Mediated by ionic interactions the inhibitor 
protein binds to negatively charged substances or surfaces. This effect is 
classified "unspecific" as opposed to the inhibition of proteinases which is a 
"specific" feature of the molecule. The rapid and almost selective uptake of 
aprotinin by phagocytes of kidney tissue is thought to be mediated by this kind 
of ionic interaction. Also, storage of aprotinin in its natural host cells, i.e. the 
bovine mast cells, is believed to be mediated by ionic binding of aprotinin to 
negatively charged heparin molecules abundant in these cells. 
One of the effects related to the dipole character of aprotinin is the inhibition 
of platelet aggregation which is observed at very high aprotinin concentrations 
(above 8 jimol/1 equivalent to approx. 400 KIU/ml) . Here, aprotinin most 
probably binds to negatively charged surface molecules of the platelet 
membrane (9). Similarly, ionic interactions with aprotinin can lead to the 
stabilization of a fluid cell membrane which might aid in maintaining certain 
cell functions for a limited time span. This effect is exploited for the long-term 
storage of blood where aprotinin is added as a stabilizer. Characteristically, the 
effects of aprotinin based on ionic interactions are fully reversible once the 
concentration of the protein falls below a certain level. - For possible future 
applications it is important to keep in mind that the preserving effect of 
aprotinin on global cell functions has been convicingly demonstrated only for 
platelets (9). Moreover, only exceptionally high aprotinin concentrations rarely 
obtained in vivo for short periods of time will promote the observed 
effects. 
5. Summary 
The aim here was to show that the molecular properties of aprotinin and the 
mechanisms by which it interacts with other molecules are known in 
considerable detail. Figure 2 provides an illustrative sketch of our ideas on the 
basic mechanisms of aprotinin action and their potential application under 
clinical conditions. With the advent of specific assay systems, the quantification 
of aprotinin in biological fluids of diverse origin as well as tissue extracts has 
become possible. This achievement allows the precise determination of 
aprotinin levels reached in vivo by well defined dosage regimens, and the 
correlation of these levels to desirable or attainable therapeutic effects of the 
inhibitor. 
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